A phase I trial in GBM patients found that IMA950 was well-tolerated as standardized therapy, with 90% of patients having at least one CD8+ T-cell immune response TUMAP and 50% responding to two or more TUMAPs (149). The gene discussed is CD8A; the disease is glioblastoma.